INMUNE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.85 USD | -2.86% |
|
+8.28% | -3.64% |
| May. 09 | Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000 | MT |
| May. 09 | Transcript : INmune Bio, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 62.47 | 231.6 | 182 | 113.8 | 202.9 | 214.6 | - | - |
| Enterprise Value (EV) 1 | 62.47 | 231.6 | 182 | 113.8 | 202.9 | 214.6 | 214.6 | 214.6 |
| P/E ratio | -7.73 x | -17 x | -5.43 x | -4.17 x | -6.74 x | -4.03 x | -4.25 x | -4.42 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 21,206 x | 1,006 x | 304 x | 1,309 x | 7,666 x | 7,401 x | 7,276 x |
| EV / Revenue | - | 21,206 x | 1,006 x | 304 x | 1,309 x | 7,666 x | 7,401 x | 7,276 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | -4,122,349 x | - | - | - | - | - |
| FCF Yield | - | - | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 10,771 | 13,448 | 17,843 | 17,946 | 18,022 | 19,782 | - | - |
| Reference price 2 | 5.800 | 17.22 | 10.20 | 6.340 | 11.26 | 10.85 | 10.85 | 10.85 |
| Announcement Date | 3/11/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0109 | 0.181 | 0.374 | 0.155 | 0.028 | 0.029 | 0.0295 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.756 | -12.23 | -29.15 | -25.95 | -29.74 | -49.82 | -50.99 | -52.09 |
| Operating Margin | - | -111,975.09% | -16,106.63% | -6,938.77% | -19,187.74% | -177,934.54% | -175,843.1% | -176,572.88% |
| Earnings before Tax (EBT) 1 | -7.678 | -12.1 | -30.34 | -27.3 | -30.01 | -49.76 | -51.01 | -52.1 |
| Net income 1 | -7.678 | -12.1 | -30.34 | -27.3 | -30.01 | -49.76 | -51.01 | -52.1 |
| Net margin | - | -110,798.17% | -16,762.43% | -7,299.2% | -19,360% | -177,732.14% | -175,898.28% | -176,627.12% |
| EPS 2 | -0.7500 | -1.010 | -1.880 | -1.520 | -1.670 | -2.690 | -2.555 | -2.455 |
| Free Cash Flow | - | - | -44.15 | - | - | - | - | - |
| FCF margin | - | - | -24,392.27% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.163 | 0.163 | 0.016 | 0.098 | 0.097 | - | 0.046 | 0.043 | 0.028 | 0.014 | 0.00467 | 0.00467 | 0.00467 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.03 | -6.478 | -6.388 | -7.443 | -5.642 | - | -6.411 | -8.528 | -8.379 | -11.02 | -11.91 | -12.92 | -13.97 |
| Operating Margin | -5,539.88% | -3,974.23% | -39,925% | -7,594.9% | -5,816.49% | - | -13,936.96% | -19,832.56% | -29,925% | -78,692.86% | -255,124.84% | -276,609.64% | -299,200.64% |
| Earnings before Tax (EBT) 1 | -9.671 | -6.903 | -6.838 | -7.725 | -5.833 | - | -6.501 | -8.563 | -8.408 | -11.02 | -11.89 | -12.89 | -13.96 |
| Net income 1 | -9.671 | -6.903 | -6.838 | -7.725 | -5.833 | -6.536 | -6.501 | -8.563 | -8.408 | -11.02 | -11.89 | -12.89 | -13.96 |
| Net margin | -5,933.13% | -4,234.97% | -42,737.5% | -7,882.65% | -6,013.4% | - | -14,132.61% | -19,913.95% | -30,028.57% | -78,750% | -254,625.27% | -276,059.96% | -298,922.27% |
| EPS 2 | -0.5500 | -0.3900 | -0.3800 | -0.4300 | -0.3200 | -0.3600 | -0.3600 | -0.4800 | -0.4700 | -0.6100 | -0.6300 | -0.6667 | -0.7200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/22 | 5/5/22 | 8/3/22 | 11/2/22 | 3/2/23 | 5/3/23 | 8/7/23 | 11/1/23 | 3/28/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -44.2 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 15 | - | - | - | - | - |
| Capex / Sales | - | - | 8,287.29% | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.85
USD
Average target price
19.67
USD
Spread / Average Target
+81.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.64% | 215M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- INMB Stock
- Financials INmune Bio, Inc.
